{
    "Clinical Trial ID": "NCT01730729",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Cabergoline)",
        "  Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.",
        "  cabergoline: Given orally"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients must have histologically confirmed metastatic breast cancer; tissue (a minimum of 3 slides) from the most recent biopsy is required for review and confirmation of eligibility; NOTE: material should ideally be from the metastatic disease, however material from the primary tumor is acceptable if that is all that is available",
        "  Patients must have stage IV breast cancer",
        "  Patients must have tumors (primary or metastatic) that stain positively for the prolactin receptor",
        "  Patients may have measurable or evaluable disease",
        "  Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan",
        "  Evaluable disease is disease that does not meet the criteria for measurable disease; examples would include patients with effusions or bone-only disease",
        "  Women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study",
        "  Patients must have a life expectancy of greater than 12 weeks",
        "  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
        "  Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment",
        "  Leukocytes >= 3,000/uL (microliter)",
        "  Absolute neutrophil count >= 1,500/uL",
        "  Platelets >= 100,000/uL",
        "  Child Pugh score =< 10",
        "  Patients must be able to swallow and retain oral medication",
        "  All patients must have given signed, informed consent prior to registration on study",
        "Exclusion Criteria:",
        "  Women who are pregnant or lactating are not eligible for study treatment",
        "  Patients who are undergoing concomitant radiotherapy are NOT eligible for participation",
        "  Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registration",
        "  Patients who are taking any herbal (alternative) medicines are NOT eligible for participation; patients must be off any such medications by the time of registration",
        "  Patients who are receiving concomitant D2-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration",
        "  Patients with known brain metastases are NOT eligible for participation",
        "  Patients with any of the following conditions or complications are NOT eligible for participation:",
        "  Uncontrolled hypertension",
        "  Known hypersensitivity to ergot derivatives",
        "  History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)",
        "  History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders",
        "  Gastrointestinal (GI) tract disease resulting in an inability to take oral medication",
        "  Malabsorption syndrome",
        "  Require intravenous (IV) alimentation",
        "  History of prior surgical procedures affecting absorption",
        "  Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Response Rate (ORR) at 2 Months",
        "  Overall Response Rate (ORR) is defined as the number of patients that achieved Complete Response (CR) or Partial Response (PR) and will be assessed after 8 weeks (2 cycles) of therapy using CT scan images and RECIST guidelines.",
        "  Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.",
        "  Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.",
        "  Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started",
        "  Time frame: After 8 weeks (2 cycles) of treament",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Cabergoline)",
        "  Arm/Group Description: Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.",
        "  cabergoline: Given orally",
        "  Overall Number of Participants Analyzed: 18",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/20 (20.00%)",
        "  Death NOS 1/20 (5.00%)",
        "  Pain 1/20 (5.00%)",
        "  Dyspnea 2/20 (10.00%)"
    ]
}